Sort
10,766 grants matching “checkpoint inhibitor”
The function of the PRMT5 methylosome in MTAP deleted cancers
$472,119William R Sellers · Broad Institute, Inc. · R01 · FY2025 · CA
Breaking down tumor immune privilege through targeted hypoxia reduction
$472,058Michael A. Curran · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Breaking down tumor immune privilege through targeted hypoxia reduction
$472,058Michael A. Curran · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Defining the Pathogenesis and Prognosis of Human Acute Interstitial Nephritis
$472,039Lloyd G Cantley · Yale University · R01 · FY2024 · DK
INTERACITONS OF HPV ONCOGENES WITH THE P53 PATHWAY
$471,896Fred Hutchinson Cancer Research Center · R01 · FY2002 · CA
Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC
$471,791Judith A. Varner · University Of California, San Diego · R01 · FY2020 · CA
Mouse Models to Elucidate p53 Regulatory Mechanisms
$471,712Geoffrey Myles Wahl · Salk Institute For Biological Studies · R01 · FY2007 · CA
Randomized Trial of Stepped Palliative Care versus Early Integrated Palliative Care in Patients with Advanced Lung Cancer
$471,698Jennifer Temel · Massachusetts General Hospital · R01 · FY2022 · CA
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy
$471,315Yong Wan · Emory University · R01 · FY2024 · CA
Targeting Lysosomal Vulnerabilities in Renal Pathogenesis
$471,216Steffan T Nawrocki · University Of Arizona · R01 · FY2023 · CA
Engineering Nanomaterials to Prime Immunity
$471,122James J. Moon · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapy
$471,003Sidi A Bencherif · Northeastern University · R01 · FY2022 · EB
Interplay between tumor and microenvironment in bone metastasis
$470,956Paul B Fisher · Virginia Commonwealth University · R01 · FY2025 · CA
Interplay between tumor and microenvironment in bone metastasis
$470,956Paul B Fisher · Virginia Commonwealth University · R01 · FY2021 · CA
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics
$470,621Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2022 · CA
Renalase inhibition for treatment of unresectable melanoma
$470,539Harriet M Kluger · Yale University · R01 · FY2019 · CA
Immunometabolic pathways enabled by PARP inhibition in breast cancer
$470,532Jennifer L. Guerriero · Brigham And Women'S Hospital · R37 · FY2022 · CA
Targeting autophagy to enhance immune checkpoint inhibition
$470,485Ravi K Amaravadi · Wistar Institute · P50 · FY2021 · CA
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
$470,418William Laurence Dahut · Division Of Clinical Sciences - Nci · ZIA · FY2019 · CA
Duke-UNC Chapel Hill Immunotherapy Training Grant
$470,297Jonathan Stuart Serody · Univ Of North Carolina Chapel Hill · T32 · FY2017 · CA
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
$470,293Katarzyna Anna Rejniak · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2021 · CA
Bone marrow-derived myeloid cell dysregulation in malignant progression of glioma
$470,284Prajwal Rajappa · Research Inst Nationwide Children'S Hosp · R01 · FY2023 · NS
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
$470,275Jerry D Glickson · University Of Pennsylvania · R01 · FY2022 · CA
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
$470,275Kavindra Nath · University Of Pennsylvania · R01 · FY2023 · CA
Exploiting oxidative stress response in uveal melanoma liver metastases
$470,236Edward Hartsough · Drexel University · R01 · FY2025 · CA